What Does Competitor’s Failure Mean to Alnylam Pharmaceuticals?
<p>According to the announcement on Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) acoramidis, the competitor of <a href='https://financialmodelingprep.com/financial-summary/ALNY'>Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)</a>, failed to significantly differentiate from placebo on 6MWD at 12 months in its Phase 3 trial in ATTR cardiomyopathy, the primary endpoint (p=0.76). </p>
<p>Despite this competitor disappointment, Alnylam Pharmaceuticals’ shares are weak, the possible reason of which can be the concerns that the unexpectedly strong performance seen in ATTRibute-CM's placebo group could similarly manifest in Apollo-B. </p>
<p>Analysts at Oppenheimer mentioned that they do not share the market's newfound skepticism and suggest buying the stock on weakness.</p>

NASDAQ:ALNY